Table 1 Basic information of the studies was included
Author name | Group | Samples | Age (years) | Intervention | Medicine | Outcomes |
|---|---|---|---|---|---|---|
Huang et al. 2020 [30] | Treatment | 50 | NR | Control + Bifidobacterium quadruple viable tablets | 1.5 g/once, tid,4 week | 1, 3 |
Control | 50 | NR | mosapride citrate | 5 mg/once, tid,4 week | ||
Guo et al. 2020 [31] | Treatment | 50 | NR | Control + Bifidobacterium quadruple viable tablets | 0.5 g/once,bid,4 week | 1, 2 |
Control | 50 | NR | mosapride citrate | 5 mg/once, tid,4 week | ||
Li et al. 2017 [32] | Treatment | 29 | 69.48 ± 5.26 | Control + Bifidobacterium quadruple viable tablets | 1.5 g/once, tid,4 week | 1, 2, 4 |
Control | 29 | 69.38 ± 5.19 | mosapride citrate | 5 mg/once, tid,4 week | ||
Liu et al. 2017 [33] | Treatment | 39 | 66.5 ± 1.5 | Control + Bifidobacterium quadruple viable tablets | 0.5 g/once,bid,8 week | 1, 2, 3 |
Control | 39 | 67.3 ± 2.0 | mosapride citrate | 5 mg/once, tid,8 week | ||
Sun et al. 2013 [34] | Treatment | 83 | 36.1 ± 6.0 | Control + Bifidobacterium quadruple viable tablets | 1.5 g/once, tid,4 week | 1, 2, 3 |
Control | 83 | 35.4 ± 5.6 | mosapride citrate | 5 mg/once, tid,4 week | ||
Yao et al. 2016 [35] | Treatment | 40 | NR | Control + Bifidobacterium quadruple viable tablets | 1.5 g/once, tid,4 week | 3 |
Control | 40 | NR | mosapride citrate | 5 mg/once, tid,4 week | ||
Zeng et al. 2013 [36] | Treatment | 47 | 41.7 ± 10.6 | Control + Bifidobacterium quadruple viable tablets | 1.5 g/once, tid,4 week | 1, 2, 3 |
Control | 47 | 50.2 ± 7.8 | mosapride citrate | 5 mg/once, tid,4 week | ||
Xie et al. 2012 [37] | Treatment | 48 | NR | Control + Bifidobacterium quadruple viable tablets | 1.5 g/once, tid,4 week | 1, 2, 3 |
Control | 48 | NR | mosapride citrate | 5 mg/once, tid,4 week | ||
Pan et al. 2012 [38] | Treatment | 40 | 52.7 ± 6.8 | Control + Bifidobacterium quadruple viable tablets | 0.5 g/once,tid,8 week | 1, 2, 3 |
Control | 40 | 52.1 ± 7.1 | mosapride citrate | 5 mg/once,tid,8 week | ||
Cao et al. 2016 [39] | Treatment | 64 | 67.82 ± 9.17 | Control + Bifidobacterium quadruple viable tablets | 0.5 g/once,bid,4 week | 1, 2, 4 |
Control | 64 | 67.86 ± 4.21 | mosapride citrate | 5 mg/once,bid,4 week | ||
Deng et al. 2020 [40] | Treatment | 45 | 70.5 ± 7.5 | Control + Bifidobacterium quadruple viable tablets | 0.5 g/once,bid,4 week | 1, 2, 4 |
Control | 45 | 70.8 ± 8.1 | mosapride citrate | 5 mg/once,tid,4 week | ||
Cheng et al. 2018 [41] | Treatment | 34 | 67.87 ± 4.22 | Control + Bifidobacterium quadruple viable tablets | 0.5 g/once,tid,4 week | 2, 4 |
Control | 34 | 67.90 ± 4.18 | mosapride citrate | 5 mg/once,1once/day,4 week | ||
Wang et al. 2020 [42] | Treatment | 52 | 40.5 ± 5.4 | Control + Bifidobacterium quadruple viable tablets | 1.5 g/once, tid, 12 week | 1 |
Control | 52 | 39.6 ± 4.8 | mosapride citrate | 5 mg/once, tid, 12 week |